Goldman Sachs downgraded Luye Pharma to Sell from Neutral with a price target of HK$3.73, up from HK$3.68. The firm sees modest product sales growth in the coming years and views earnings improvement from potential debt pay-down as reflected in the share price, the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>